about
Incretins and the intensivist: what are they and what does an intensivist need to know about them?The gut-brain axis in the critically ill: is glucagon-like peptide-1 protective in neurocritical care?Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and meta-analysisStress Induced Hyperglycemia and the Subsequent Risk of Type 2 Diabetes in Survivors of Critical IllnessProbable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection.Stress ulceration: prevalence, pathology and association with adverse outcomes.Dysglycemia and Glucose Control During Sepsis.Occult upper gastrointestinal mucosal abnormalities in critically ill patients.Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study.Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study.Critical Illness Is Associated With Impaired Gallbladder Emptying as Assessed by 3D Ultrasound.The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1.Prior exposure to hyperglycaemia attenuates the relationship between glycaemic variability during critical illness and mortality.Energy-Dense Formulae May Slow Gastric Emptying in the Critically Ill.Glycemia Is Related to Impaired Cerebrovascular Autoregulation after Severe Pediatric Traumatic Brain Injury: A Retrospective Observational Study.Withholding Stress Ulcer Prophylaxis To Mechanically Ventilated Enterally-Fed Critically Ill Patients Appears Safe: A Randomised Double-Blind Placebo Controlled Pilot Study.Corrigendum: Glycemia Is Related to Impaired Cerebrovascular Autoregulation after Severe Pediatric Traumatic Brain Injury: A Retrospective Observational Study.Long-term mortality of critically ill patients with diabetes who survive admission to the intensive care unit.Stroke following inadvertent carotid artery catheterisation.Cerebral metabolic effects of strict versus conventional glycaemic targets following severe traumatic brain injury.Glycaemic control targets after traumatic brain injury: a systematic review and meta-analysis.Antecedent Hypoglycemia Does Not Attenuate the Acceleration of Gastric Emptying by Hypoglycemia.Comparison of macroscopic abnormalities in patients receiving routine pantoprazole when compared to placebo.Exogenous glucagon-like peptide-1 attenuates glucose absorption and reduces blood glucose concentration after small intestinal glucose delivery in critical illness.Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality.A prospective observational study of the effect of critical illness on ultrastructural and microscopic morphology of duodenal mucosa.Nutrient-stimulated gallbladder emptying is incomplete during critical illness as assessed by 3D ultrasound.Personalised glucose therapy: glucose targets in critically ill patients with pre-existing poorly controlled type 2 diabetes.Incident Diabetes in Survivors of Critical Illness and Mechanisms Underlying Persistent Glucose Intolerance: A Prospective Cohort StudySystematic review of incretin therapy during peri-operative and intensive careHyperglycemia Potentiates the Slowing of Gastric Emptying Induced by Exogenous GLP-1Glucagon-Like Peptide 1 Attenuates the Acceleration of Gastric Emptying Induced by Hypoglycemia in Healthy SubjectsIncretin Physiology and Pharmacology in the Intensive Care UnitGut dysmotility in the ICU: diagnosis and therapeutic optionsGallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients
P50
Q26995464-ADCD9755-3DE4-4764-82BD-52781A88A848Q33751723-4F0ED389-288D-43F6-BC46-FD02CA44687BQ34541305-636D9A52-1BE7-46D8-9E38-1DDAC23A3D26Q36185664-D667AA49-69C9-41B2-89A7-709261041939Q36327745-757A7C90-C30D-4A41-8A35-BD022FD1F108Q38230155-69CD5DFB-EFF0-4DF8-AE72-4CF673E577FDQ38845330-A12D1DB1-A254-44AA-A282-6A794705D48DQ39102984-4921850A-F7B0-4644-8865-FE108037FC54Q39382428-6E9CD287-A5B6-470C-A23C-004324BE3106Q39675141-EB42A231-EBF7-4AC8-A25F-BDB970092770Q39856851-C8C60F4E-16B7-418C-9668-1A660A002ED0Q40036292-B06BDB5E-FE92-4D92-A376-BB63AEDD5F02Q40591137-0B9FF2D1-3FA7-4C05-814F-BC540F0B0A59Q40874745-49B8D96E-3486-4A3B-BA45-CA3B321E10DFQ42168172-4C4743CA-6CAF-4E8B-95D0-7D14CC8C2A6AQ45844102-040AC2A6-C52F-452D-BCD0-CD9C264735BFQ47097199-078B6629-45E2-483F-A362-D1F975661231Q47373355-869B8003-EF7D-4CBF-9339-DA04165C9EEBQ47379574-967C5E0B-64F9-458C-BC1A-FC6A9B073F5DQ47840690-0454774F-A28F-4B43-BECD-044F2DBC132AQ47851374-296B0440-4BDB-4A5E-93CF-4572506F1184Q49651404-546EBC94-3F7D-451A-95CB-048FD4F002FAQ50234189-4AF968AA-8DC9-417E-A514-E0E310937CE2Q50884624-8BB0C869-0230-4BB1-8F2A-40E0F9FCBB01Q51323673-CC7238C4-BEBF-4075-912C-038BA7048F9EQ53091493-28D96D31-8D9B-4281-9F84-FF89C767D388Q54842026-A6A610E5-6E87-4328-89DE-E4665ECC9B21Q55079046-635CA279-32BC-47F6-A1E2-F50751DD21C9Q58609845-51FE3F79-D206-4F95-B162-18BF502A3EE6Q59126600-569A2639-BA7D-4FCF-94BA-21AD30F60554Q62478668-4B821219-F6D7-422F-BCF3-B3B2A3FE32D5Q62478762-98C21C2E-2733-4C64-8095-96512D93A0B5Q91738474-9AD3F052-D9D9-42D3-9573-D5905951AB46Q92264337-4919FCE8-9E84-4897-9ED8-E8162506092DQ92747286-653D7AEC-67BB-4A37-9377-764F701F1060
P50
description
investigador
@es
researcher
@en
name
Mark P Plummer
@en
type
label
Mark P Plummer
@en
prefLabel
Mark P Plummer
@en
P31
P496
0000-0002-9640-1911